DBV Technologies (NASDAQ:DBVT) Hits New 1-Year High Following Analyst Upgrade

DBV Technologies S.A. (NASDAQ:DBVT) hit a new 52-week high during mid-day trading on Wednesday after Citizens Jmp raised their price target on the stock from $21.00 to $45.00. Citizens Jmp currently has a market outperform rating on the stock. DBV Technologies traded as high as $26.19 and last traded at $22.7570, with a volume of 1528755 shares. The stock had previously closed at $17.98.

DBVT has been the topic of several other reports. Citigroup reaffirmed an “outperform” rating on shares of DBV Technologies in a research report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $35.00 price objective (up previously from $20.00) on shares of DBV Technologies in a report on Monday. Guggenheim reiterated a “buy” rating and issued a $51.00 price objective (up from $35.00) on shares of DBV Technologies in a research report on Wednesday. Zacks Research raised shares of DBV Technologies from a “strong sell” rating to a “hold” rating in a research note on Monday, September 29th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of DBV Technologies in a research report on Monday, December 8th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $35.38.

Institutional Trading of DBV Technologies

Hedge funds and other institutional investors have recently modified their holdings of the company. New York State Common Retirement Fund acquired a new stake in shares of DBV Technologies in the third quarter valued at $34,000. Two Sigma Investments LP bought a new stake in DBV Technologies in the third quarter worth about $167,000. Citadel Advisors LLC acquired a new stake in DBV Technologies in the 3rd quarter valued at about $220,000. DLD Asset Management LP acquired a new stake in DBV Technologies in the 3rd quarter valued at about $250,000. Finally, Nan Fung Trinity HK Ltd. bought a new position in shares of DBV Technologies during the 2nd quarter valued at about $340,000. Institutional investors own 71.74% of the company’s stock.

DBV Technologies Stock Performance

The company’s 50 day moving average price is $15.23 and its 200-day moving average price is $11.72. The company has a market cap of $864.24 million, a price-to-earnings ratio of -4.16 and a beta of -1.10.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.